DrugPatentWatch Database Preview» See Plans and Pricing
« Back to Dashboard
Summary for Patent: 8,124,350
|Title:||Methods and products for evaluating an immune response to a therapeutic protein|
|Abstract:||The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.|
|Inventor(s):||Subramanyam; Meena (Stoneham, MA), Amaravadi; Lakshmi (Natick, MA), Wakshull; Eric (Princeton, MA), Lynn; Frances (Somerville, MA), Panzara; Michael (Winchester, MA), Barbour; Robin Mcdaid (Walnut Creek, CA), Taylor; Julie Elizabeth (San Francisco, CA)|
|Assignee:||Biogen Idec MA Inc. (Cambridge, MA) Elan Pharmaceuticals, Inc. (South San Francisco, CA)|
|Patent Claims:||1. A method of detecting a reduction in therapeutic efficacy of natalizumab in a subject that has been administered natalizumab, the method comprising: performing an antibody
detection assay to determine whether two or more biological samples taken at different time points from the subject contain a level of anti-natalizumab antibody that is at least a threshold level of anti-natalizumab antibody, wherein the threshold level
is at least two standard deviations above a mean level of anti-natalizumab antibody measured in an untreated patient population, and, wherein the presence of the threshold level of anti-natalizumab antibody in the two or more samples indicates a
reduction in, or absence of, therapeutic efficacy of natalizumab.
2. The method of claim 1, wherein the level of anti-natalizumab antibody is measured in a first aliquot of the biological sample; and wherein the method further comprises determining the binding specificity of the anti-natalizumab antibody for natalizumab.
3. The method of claim 2, wherein the binding specificity of the anti-natalizumab antibody is determined done in a second aliquot of the biological sample.
4. The method of claim 1, wherein the level of anti-natalizumab antibody is determined by comparing levels of binding to a labeled VLA-4 binding antibody measured in the presence of two or more different amounts of unlabeled VLA-4 binding antibody.
5. The method of claim 1, wherein the level of anti-natalizumab antibody is determined by comparing levels of binding to an immobilized VLA-4 binding antibody measured in the presence of two or more different amounts of soluble VLA-4 binding antibody.
6. The method of claim 4, wherein the level of anti-natalizumab antibody is determined by comparing a first level of binding to a labeled VLA-4 binding antibody measured in the presence of a first amount of unlabeled VLA-4 binding antibody to a second level of binding to a labeled VLA-4 binding antibody measured in the presence of a second amount of unlabeled VLA-4 binding antibody.
7. The method of claim 1, wherein a bridging ELISA assay is performed to determine whether the biological sample contains the threshold level of anti-natalizumab antibody.
8. The method of claim 1, wherein a first level of binding to natalizumab is determined in a first immunoassay for a first aliquot of the biological sample, and wherein a second level of binding to natalizumab is determined in a second immunoassay for a second aliquot of the biological sample, wherein the second immunoassay is spiked with a greater amount of unlabeled soluble VLA-4 binding antibody than the first immunoassay, and wherein the biological sample contains at least a threshold level of anti-natalizumab antibody if the first level of binding is greater than a reference level and the second level of binding is less than the first level of binding.
9. The method of claim 8, wherein the reference level is a level of binding measured for a reference amount of antibody that binds to natalizumab.
10. The method of claim 9, wherein the reference amount is about 500 ng/ml.
11. The method of claim 8, wherein the first and second immunoassays are bridging ELISA assays.
12. The method of claim 1, wherein the subject has multiple sclerosis, rheumatoid arthritis, or Crohn's disease.
13. The method of claim 1, further comprising selecting a therapeutic regimen for the subject if a threshold level of anti-natalizumab antibody is determined to be present in at least two biological samples from the subject.
14. The method of claim 13, wherein selecting a therapeutic regimen comprises, evaluating a current therapy of the subject, determining a new therapy for the subject, modifying a current therapy of the subject, or stopping a current therapy of the subject.
15. The method of claim 14, wherein a current therapy comprises administering natalizumab to the subject.
16. The method of claim 1, wherein the subject is a human subject.
Summary for Patent: Start Trial
|PCT Filed||April 04, 2006||PCT Application Number:||PCT/US2006/012493|
|PCT Publication Date:||October 12, 2006||PCT Publication Number:||WO2006/107962|
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Biogen Idec||TYSABRI||natalizumab||VIAL; SINGLE-USE||125104||001||2004-11-23||Start Trial||Biogen Idec MA Inc. (Cambridge, MA) Elan Pharmaceuticals, Inc. (South San Francisco, CA)||2025-04-04||RX||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Estimated Expiration|
|World Intellectual Property Organization (WIPO)||2006107962||Start Trial|
|United States of America||2009176256||Start Trial|
|United States of America||2012195884||Start Trial|
|United States of America||2015071917||Start Trial|
|United States of America||2018088127||Start Trial|
|United States of America||8871449||Start Trial|
|>Country||>Patent Number||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.